SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise against tough head and neck cancer
Disease control CompletedThis phase 2 trial tested whether adding tiragolumab to atezolizumab (Tecentriq) helps shrink tumors better than atezolizumab alone in people with advanced head and neck cancer that has come back or spread. The study enrolled 123 adults whose tumors have a specific protein (PD-L1…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail shows promise for tough head and neck cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—camrelizumab (an immunotherapy), cetuximab (a targeted therapy), and chemotherapy—as a first treatment for people with head and neck cancer that has come back or spread. The study enrolled 41 participants and measured how man…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cancer drug SGN-B6A tested for safety in chinese patients
Disease control CompletedThis early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control CompletedThis study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people with head and neck cancer that has returned or spread and is no longer responding to standard treatments. About 408 participants were randomly assigned to receive the combination…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug shows promise for tough head and neck cancers
Disease control CompletedThis study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and …
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
Experimental cocktail aims to reboot immune attack on resistant tumors
Disease control CompletedThis early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 26, 2026 13:24 UTC
-
Could setanaxib boost keytruda against head and neck cancer?
Disease control CompletedThis Phase 2 trial tested whether adding setanaxib (an experimental oral drug) to the standard immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with recurrent or metastatic squamous cell carcinoma of the head and neck. 55 adults whose cancer…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Calliditas Therapeutics Suisse SA • Aim: Disease control
Last updated Jun 26, 2026 13:14 UTC
-
Could a seed protein stop oral cancer? early study hints at promise
Knowledge-focused CompletedThis early-phase study looked at whether a protein from the Maackia amurensis seed (MASL) can target a receptor called podoplanin found on oral cancer and precancerous cells. Researchers measured how much of this receptor was present in tissue samples from 18 adults with suspicio…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: EARLY_PHASE1 • Sponsor: Rowan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New study explores what matters most to patients with high-risk head and neck skin cancer
Knowledge-focused CompletedThis study looked at how 78 patients with high-risk skin cancer on the head or neck felt about their treatment decisions, quality of life, and satisfaction with care. Researchers used standard questionnaires to measure these factors at two points: right after a team of doctors di…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC